ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO812

Plasma Galactose-Deficient IgA1/C3 Ratio Is Strongly Associated with Disease Progression in IgA Nephropathy

Session Information

Category: Glomerular Diseases

  • 1202 Glomerular Diseases: Immunology and Inflammation


  • Chen, Pei, Peking University First Hospital, Beijing, China
  • Yu, Gui-zhen, Peking University First Hospital, Beijing, China
  • Zhang, Xue, Peking University First Hospital, Beijing, China
  • Shi, Sufang, Peking University First Hospital, Beijing, China
  • Lv, Jicheng, Peking University First Hospital, Beijing, China
  • Zhang, Hong, Peking University First Hospital, Beijing, China

Galactose-deficient IgA1 (Gd-IgA1) and C3 mesangial codeposition is a hallmark of IgA nephropathy (IgAN). In this large cohort study, we aim to evaluate Gd-IgA1/C3 ratio in the progression of IgAN.


In this study, we included 1157 IgAN patients with a median follow-up period of 42 months. Plasma Gd-IgA1 was measured at the time of diagnosis using a lectin-based ELISA. The composite kidney failure event was defined by 50% decline in eGFR or ESRD and renal survival was modeled using the Cox proportional hazards method and restricted cubic splines.


Although high plasma Gd-IgA1 levels were associated with the risk of kidney progression events, the association was not in a linear relationship. While the correlation between plasma Gd-IgA1/C3 ratio and risk of kidney failure was a linear relationship. After adjusted for traditional risk factors, higher levels of Gd-IgA1/C3 ratio was independently associated with a greater risk of deterioration in renal function with a HR of 2.15 (95% CI=1.21–3.81, P=0.008) per ln(Gd-IgA1/C3). In reference to the first quartile, the risk of kidney progression event increased such that the HR for the second quartile was 1.84 (95% CI=1.05–3.24, P=0.034), 1.79 (95% CI=1.02–3.12, P=0.041) for the third, and 2.08 (95% CI=1.22–3.54, P=0.007) for the fourth quartile of the Gd-IgA1/C3 ratio.


Plasma Gd-IgA1/C3 ratio was an independent risk factor for kidney progression events.

Cox regression model associations of baseline plasma Gd-IgA1/C3 levels with incidence of composite end point.
 HR (95% CI) and P value
 UnadjustedModel 1Model 2Model 3
Per ln(Gd-IgA1/C3)3.00 (1.73-5.21)3.02 (1.74-5.24)2.68(1.59-4.53)2.15(1.21-3.81)
P value8.9×10-58.1×10-52.2×10-40.008
Gd-IgA1/C3 quartiles    
21.68(0.99-2.85)1.61(0.94-2.76)1.63(0.95-2.80)1.84 (1.05-3.24)
P value0.0550.0820.0760.034
31.97(1.17-3.31)1.90(1.13-3.22)2.10(1.24-3.55)1.79 (1.02-3.12)
P value0.0100.0160.0060.041
42.49(1.51-4.12)2.47(1.49-4.07)2.29(1.39-3.80)2.08 (1.22-3.54)
P value3.5×10-44.3×10-40.0010.007

Model 1 was adjusted for sex and age. Model 2 was adjusted for covariates in model 1 plus eGFR, proteinuria, and mean arterial blood pressure. Model 3 was adjusted for covariates in model 2 plus Oxford MESTC scores and steroids or other immunosuppressive agents .